Drug Class Detail

Drug Class Immune Checkpoint Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AZD4635 Immune Checkpoint Inhibitor 99 AZD4635 binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241).
NLG802 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 NLG802 is a prodrug of indoxomid, which inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (AACR Annual Meeting 2017, Abstract nr 4076).
CX-188 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Limited information is currently available on CX-188, a putative PD-1 probody (Dec 2018).
LZM009 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 LZM009 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
MSB2311 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 MSB2311 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
Avelumab Bavencio MSB0010718C Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in patients with metastatic Merkel cell carcinoma and urothelial carcinoma (FDA.gov).
FAZ053 FAZ-053|FAZ 053 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 FAZ053, is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
PDR001 Spartalizumab Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
MK-7162 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 MK-7162 inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (NCI Thesaurus).
BMS-986207 Immune Checkpoint Inhibitor 99 BMS-986207 is a human monoclonal antibody against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which removes the immune checkpoint blockade by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155) (NCI Drug Dictionary).
AGEN2034 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 AGEN2034 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086).
CPI-006 CD73 Antibody 6 Immune Checkpoint Inhibitor 99 Limited information is currently available on CPI-006 a putative monoclonal antibody against NT5E (CD73) (Jul 2018).
TSR-022 Immune Checkpoint Inhibitor 99 TIM-3 Antibody 5 TSR-022 is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
BMS-986179 CD73 Antibody 6 Immune Checkpoint Inhibitor 99 BMS-986179 is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 29914571).
MK-7684 Immune Checkpoint Inhibitor 99 MK-7684 is antagonistic against against T-cell immunoreceptor with Ig and ITIM domains (TIGIT), which removes the immune checkpoint blockade by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155) (NCI Drug Dictionary).
XmAb20717 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 XmAb20717 is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).
TTI-622 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 TTI-622 is fusion, consisting of SIRPa fused to the human IgG4 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 2709).
NZV930 SRF373 CD73 Antibody 6 Immune Checkpoint Inhibitor 99 Limited information is currently available on NZV930, a putative monoclonal antibody against NT5E (CD73) (Jul 2018).
Indoximod 1-methyl-d-tryptophan|D-1MT|1-MT|NLG-8189 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 Indoximod inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (PMID: 26033215, PMID: 17234791).
CS1003 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 CS1003 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
KHK2455 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 KHK2455 is an IDO1 inhibitor, which results in reduced levels of kynurenine, leading to immune cell activation and subsequent tumor growth inhibition of cancer cells expressing IDO-1 (NCI Drug Dictionary).
GB226 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 GB226 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
CC-90002 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 CC-90002 is monoclonal antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856).
Cemiplimab Libtayo REGN2810|SAR439684 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation (FDA.gov).
LAG525 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 LAG525 is a monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth (NCI Drug Dictionary).
JNJ-63723283 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 JNJ-63723283 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28943093).
Epacadostat INCB024360 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 Epacadostat (INCB024360) inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (PMID: 20197554).
PBF-509 NIR178 Immune Checkpoint Inhibitor 99 PBF-509 binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241, PMID: 28582704).
TSR-042 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 TSR-042 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (Eur J Cancer 2016 Dec; 69 (Suppl 1):S102, Abstract # 310).
Pembrolizumab Keytruda MK-3475 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, and in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC (FDA.gov).
AO-104 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 AO-104 is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856).
BMS-986258 ONO 7807 Immune Checkpoint Inhibitor 99 TIM-3 Antibody 5 BMS-986258 is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (NCI Thesaurus).
AGEN1884 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 AGEN1884 is an antibody that targets CTLA-4, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).
IPH53 CD73 Antibody 6 Immune Checkpoint Inhibitor 99 Limited information is currently available on IPH53, a putative monoclonal antibody against NT5E (CD73) (Jul 2018).
TTI-621 SIRPalpha-Fc CD47 Antibody 13 Immune Checkpoint Inhibitor 99 TTI-621 (SIRPalpha-Fc) is a fusion, consisting of SIRPa fused to the human IgG1 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells (PMID: 27856600, PMID: 28286286) may also stimulate cytotoxic T-cells (PMID: 29873865).
Camrelizumab SHR-1210|INCSHR-1210 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Camrelizumab (SHR-1210) is an antibody that targets PD-1 (PDCD1) and inhibits binding of PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in activation of anti-tumor immune response and decreased tumor growth (PMID: 29358502).
Relatlimab BMS-986016 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 Relatlimab (BMS-986016) is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 9520-9520).
AMP-224 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 AMP-224 is a fusion protein comprised of the extracellular domain of PD-L2 (PDCD1LG2) and the Fc region of IgG1, which binds to the PD-1 (PDCD1) receptor thereby potentially resulting in restoration of the T-cell mediated immune response (NCI Drug Dictionary).
NI-1701 CD19 Antibody 7 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 NI-1701 is a bispecific antibody to CD47 and CD19 designed to selectively engage malignant B-cells (PMID: 29743205) and block CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856).
Nivolumab Opdivo MDX-1106|BMS-936558 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (NCI Drug Dictionary). Opdivo (nivolumab) is FDA approved for the treatment of metastatic melanoma, squamous NSCLC, metastatic small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's lymphoma, hepatocellular carcinoma, and for dMMR or MSI-H colorectal cancer as a single agent or in combination with Yervoy (ipilimumab) (FDA.gov).
Atezolizumab Tecentriq RG7446|MPDL3280A Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).
GDC-0919 Navoximod NLG919|RG6078 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 GDC-0919 (Navoximod) inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (PMID: 25054064).
Sym023 Immune Checkpoint Inhibitor 99 TIM-3 Antibody 5 Sym023 is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5629).
Oleclumab MEDI9447 CD73 Antibody 6 Immune Checkpoint Inhibitor 99 Oleclumab (MEDI9447) is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 27622077).
AK104 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 AK104 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
REGN3767 REGN 3767 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 REGN3767 is a monoclonal antibody that targets LAG3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).
HLX10 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 HLX10 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
Pidilizumab Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Pidilizumab is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
NI-1801 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 NI-1801 is a bispecific antibody to CD47 and mesothelin, designed to target tumor cells expressing mesothelin and block CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (PMID: 28286286) may also stimulate cytotoxic T-cells (PMID: 29873856).
AO-108 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 AO-108 is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856).
BMS-986218 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 BMS-986218 is a 2nd generation antibody that targets CTLA4, resulting in T-cell activation and increased anti-tumor immune response (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B33).
Sym021 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Sym021 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3822).
JS001 JS-001|TAB001 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 JS001 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; J Clin Oncol 35, 2017 (suppl; abstr e14581)).
BGB-A333 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 BGB-A333 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
BMS-986249 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 BMS-986249 is a 2nd generation antibody that targets CTLA4, resulting in T-cell activation and increased anti-tumor immune response (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B33).
M7824 MSB0011359C Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 TGFBR2 Antibody 2 M7824 is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798).
OMP-313M32 Immune Checkpoint Inhibitor 99 OMP-313M32 is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating the immune response to tumors (AACR, Vol 58, April 2017, Abstract #599).
IPH52 Immune Checkpoint Inhibitor 99 Limited information is currently available on IPH52, a putative monoclonal antibody against ENTPD1 (CD39) (Jul 2018).
Sintilimab Tyvyt IBI308 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Sintilimab (IBI308) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in enhanced anti-tumor immune response (PMID: 29300693, PMID: 29900038).
Hu5F9-G4 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 Hu5F9-G4 is a humanized monoclonal antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (PMID: 26390038, PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856).
BGB-A317 Tislelizumab Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (NCI Drug Dictionary).
AK105 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 AK105 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
LY3321367 Immune Checkpoint Inhibitor 99 TIM-3 Antibody 5 LY3321367, is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
CX-072 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 CX-072 is a prodrug consisting of a monoclonal antibody to PD-L1 (CD274) and a masking peptide that is cleaved by proteases specific to tumor cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3072-3072).
BMS-936559 MDX-1105 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 BMS-936559 is a PD-1 (PDCD1) human monoclonal antibody, which blocks the binding of PD-L1 (CD274) resulting in a T-cell mediated immune response and possible tumor regression (PMID: 22658128).
Effi-DEM OSE-172 Immune Checkpoint Inhibitor 99 Effi-DEM (OSE-172) is a monoclonal antibody to the SIRPa receptor that blocks the CD47-SIRPa interaction to promote macrophage phagocytosis of tumor cells and may stimulate cytotoxic T-cells (PMID: 29873865).
ABBV-181 ABBV181|ABBV 181 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 ABBV-181 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
Sym022 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 Sym022 is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5626).
MEDI0680 AMP-514 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 MEDI0680 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
Preladenant MK-3814|SCH420814 Immune Checkpoint Inhibitor 99 Preladenant (MK-3814) binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 22676397, PMID: 19109019).
GLS-010 AB122 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 GLS-010 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).
HLX20 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 HLX20 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29932513).
MGD013 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 PD-L1/PD-1 antibody 48 MGD013 is an engineered antibody protein that targets both PDCD1 (PD-1) and LAG3 resulting in enhanced T-cell mediated anti-tumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) 3217).
AO-176 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 AO-176 is an antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856).
BMS-986205 BMS986205|BMS 986205|ONO-7701 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 BMS-986205 inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (PMID: 29167110).
BI 754111 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 BI 754111 is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4547).
FS118 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 PD-L1/PD-1 antibody 48 FS118 is a bispecific antibody that targets both PD-1 (PDCD1) and LAG3, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).
MK-4280 Immune Checkpoint Inhibitor 99 LAG3 Antibody 10 MK-4280 is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (PMID: 29359507).
ALX148 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 ALX148 is a fusion, consisting of the Fc region of immunoglobulin fused to the CD47 SIRPa-binding domain, that blocks the ability of CD47 to bind SIRPa on macrophages thereby promoting phagocytosis of tumor cells (PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856).
SRF231 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 SRF231 is monoclonal antibody against CD47 that binds to and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells (Blood 2016 128:1843, PMID: 28286286) and may also stimulate cytotoxic T-cells (PMID: 29873856).
Ipilimumab Yervoy BMS-734016 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (NCI Drug Dictionary). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma and microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (FDA.gov).
BCD-100 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 BCD-100 is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29300693).
BGB-5777 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 BGB-5777 inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (Neuro-Oncology, Volume 19, Issue suppl_4, 1 June 2017, Pages iv32).
KN035 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 KN035 is a nanobody that targets PD-L1 (CD274) and prevents interaction with PD-1 (PDCD1), potentially resulting in decreased tumor growth (PMID: 28280600).
Tremelimumab CP-675,206 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 Tremelimumab binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (NCI Drug Dictionary).
MGA012 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 MGA012 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl, TPS2601).
MK-1308 CTLA4 Antibody 9 Immune Checkpoint Inhibitor 99 MK-1308 is a monoclonal antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response and decreased tumor growth (NCI Drug Dictionary).
MBG453 Immune Checkpoint Inhibitor 99 TIM-3 Antibody 5 MBG453 is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (PMID: 29544515).
HMBD004 CD47 Antibody 13 Immune Checkpoint Inhibitor 99 HMBD004 s a bispecific antibody to CD47 and CD33 that blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856).
LY3381916 IDO1 Inhibitor 9 Immune Checkpoint Inhibitor 99 LY3381916 inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (NCI Thesaurus).
Durvalumab Imfinzi MEDI4736 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer (FDA.gov).
LY3300054 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 LY3300054, is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29712568).
MTIG7192A RO7092284|RG6058 Immune Checkpoint Inhibitor 99 MTIG7192A is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating the immune response to tumors (PMID: 29991503).
CPI-444 V81444 Immune Checkpoint Inhibitor 99 CPI-444 binds to and inhibits A2A (ADORA2A) on immune cells, which may increase anti-tumor immune response and inhibit tumor growth by blocking binding of the immunosuppressive metabolite, adenosine (Cancer Immunol Res 2016;4(11 Suppl):Abstract nr PR04, PMID: 29923026).
BI 754091 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 BI 754091 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212).
JNJ-61610588 JNJ 61610588 Immune Checkpoint Inhibitor 99 JNJ-61610588 is an immune checkpoint inhibitor and monoclonal antibody that targets the T-cell receptor, VISTA (PD1H), V-type immunoglobulin domain-containing suppressor of T-cell activation, to evoke an anti-tumor response (NCI Drug Dictionary).
PF-06801591 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 PF-06801591 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).
CS1001 WBP3155 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 CS1001 (WBP3155) is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395).
CA-170 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 CA-170 is a small molecule inhibitor of PD-L1 (CD274) and V-domain Ig suppressor of T-cell activation (VISTA), which may stimulate T-cell mediated immune response against tumor cells (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD).
Molecular Profile Protein Effect Treatment Approaches